Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis

Experimental and Therapeutic Medicine

Volumn 7, Issue 5, 2014, Pages 1342-1348

  Zhang, Wei ^a,b   Chen, Xiaowei ^b   Huang, Ling ^b   Lu, Ning ^b   Zhou, Lei ^b   Wu, Guojie ^b   Chen, Yuguo ^a  

^a SHANDONG UNIVERSITY   (China)

^b YANTAISHAN HOSPITAL   (China)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Mortality; Prognosis; Severe sepsis

Indexed keywords

ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOCORTICOID; LACTIC ACID; VASOACTIVE AGENT;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; AGED; APACHE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY DISTRESS; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; THROMBOSIS;

EID: 84896848827     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1566     Document Type: Article

References (32)

1. Bone RC: A critical evaluation of new agents for the treatment of sepsis. JAMA 266: 1686-1691, 1991.
2. Hicks P and Cooper DJ; Australian and New Zealand Intensive Care Society (ANZICS) Board and Clinical Trials Group Executive Committee: The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Resusc10: 8, 2008.
3. Brun-Buisson C, Doyon F, Carlet J, et al: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA274: 968-974, 1995.
4. Tamion F, Le Cam-Duchez V, Menard JF, Girault C, Coquerel A and Bonmarchand G: Erythropoietin and renin as biological markers in critically ill patients. Crit Care8: R328-R335, 2004.
5. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD and EguchiS: AngiotensinII signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112: 417-428, 2007.
6. Crouser ED: Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion4: 729-741, 2004.
7. Salgado DR, Rocco JR, Silva E and Vincent JL: Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach? Expert Opin Ther Targets14: 11-20, 2010.
8. Schmidt C, Höcherl K, Kurt B, Moritz S, KurtzA and BucherM: Blockade of multiple but not single cytokines abrogates downregulation of angiotensinII type-I receptors and anticipates septic shock. Cytokine49: 30-38, 2010.
9. Wan L, Langenberg C, Bellomo R and MayCN: AngiotensinII in experimental hyperdynamic sepsis. Crit Care13: R190, 2009.
10. Yunge M and Petros A: Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child82: 388-389, 2000.
11. No authors listed: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions forsepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864-874, 1992.
12. Mehta RL, Kellum JA, Shah SV, Molitoris BA, RoncoC, WarnockDG, Levin A; Acute Kidney Injury Network: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11: R31, 2007.
13. Bernard GR, Artigas A, Brigham KL, et al: The American-European Consensus Conference of ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149 (3 Pt 1): 818-824, 1994.
14. Kreger BE, Craven DE and McCabe WR: Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612patients. Am J Med68: 344-355, 1980.
15. Bone RC, Fischer CJ Jr, Clemmer TP, Slotman GJ, MetzCA and BalkRA: Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med17: 389-393, 1989.
16. Sprung CL, Peduzzi PN, Shatney CH, et al: Impact of encephalopathy on mortality in the sepsis syndrome. Crit Care Med18: 801-806, 1990.
17. Calandra T, Baumgartner JD, Grau GE, et al: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis161: 982-987, 1990.
18. Clemmer TP, Fischer CJ Jr, Bone RC, Slotman GJ, MetzCA and ThomasFO: Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med20: 1395-1401, 1992.
19. Zabolotskikh IB, Musaeva TS and Denisova EA: Validity of APACHE II, APACHE III, SAPS 2, SAPS 3 and SOFA scales in obstetric patients with sepsis. Anesteziol Reanimatol Nov-Dec: 55-57, 2012.
20. Chen SJ, Chao TF, Chiang MC, Kuo SC, Chen LY, YinT, Chen TL and Fung CP: Prediction of patient outcome from Acinetobacter baumannii bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores. Intern Med 50: 871-877, 2011.
21. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V and EgidoJ: Inflammation and angiotensinII. Int J Biochem Cell Biol35: 881-900, 2003.
22. Lund DD, Brooks RM, Faraci FM and HeistadDD: Role of angiotensinII in endothelial dysfunction induced by lipopolysaccharide in mice. Am J Physiol Heart Circ Physiol293: H3726-H3731, 2007.
23. Yao S, Feng D, Wu Q, Li K and Wang L: Losartan attenuates ventilator-induced lung injury. J Surg Res145: 25-32, 2008.
24. Wiel E, Pu Q, Leclerc J, et al: Effects of the angiotensin-converting enzyme inhibitor perindopril on endothelial injury and hemostasis in rabbit endotoxic shock. Intensive Care Med30: 1652-1659, 2004.
25. Hagiwara S, Iwasaka H, Hidaka S, Hasegawa A, KogaH and NoguchiT: Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats. Intensive Care Med35: 1471-1478, 2009.
26. Almeida WS, Maciel TT, Di Marco GS, Casarini DE, CamposAH and Schor N: Escherichiacoli lipopolysaccharide inhibits renin activity in human mesangial cells. Kidney Int69: 974-980, 2006.
27. Bucher M, Hobbhahn J and Kurtz A: Nitric oxide-dependent down-regulation of angiotensinII type2 receptors during experimental sepsis. Crit Care Med29: 1750-1755, 2001.
28. Dunn CW and Horton JW: Role of angiotensinII in neonatal sepsis. Circ Shock40: 144-150, 1993.
29. Graninger M, Marsik C, Dukic T, Wagner OF, BlannAD and JilmaB: Enalapril does not alter adhesion molecule levels in human endotoxemia. Shock19: 448-451, 2003.
30. Bexelius TS, Blomberg J, LuYX, et al: Losartan to prevent hyperenzymemia after endoscopic retrograde cholangiopan-creatography: A randomized clinical trial. World J Gastrointest Endosc4: 506-512, 2012.
31. Dong LW, Chang YZ, Tong LJ, Tang J, Su JY and TangCS: Role of regulatory peptide in pathogenesis of shock. Sci China B37: 162-169, 1994.
32. Annane D, Sébille V, Troché G, Raphaël JC, GajdosP and BellissantE: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA283: 1038-1045, 2000.